Keywords: Abbott,, PanGenetics, Licensing, Chronic pain, NGF

Abbott to acquire PanGenetics’ novel investigational biologic for chronic pain for up to $190 million

Article | 13 November 2009

Print This

US health care major Abbott says it has signed a definitive agreement to acquire the global rights to Dutch firm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in